Atyr PHARMA (NASDAQ:ATYR) Given “Buy” Rating at HC Wainwright

Atyr PHARMA (NASDAQ:ATYR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $35.00 price objective on the stock.

Several other equities analysts also recently weighed in on ATYR. Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 target price on shares of Atyr PHARMA in a research note on Wednesday, August 14th. Jefferies Financial Group started coverage on Atyr PHARMA in a research report on Thursday, September 5th. They set a “buy” rating and a $9.00 price target for the company. Finally, Wells Fargo & Company assumed coverage on Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 target price on the stock.

Atyr PHARMA Trading Down 3.6 %

Shares of ATYR stock opened at $3.17 on Tuesday. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company’s fifty day simple moving average is $3.01. The company has a market cap of $266.10 million, a price-to-earnings ratio of -3.37 and a beta of 1.07. Atyr PHARMA has a 12 month low of $1.14 and a 12 month high of $3.80.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, equities analysts predict that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.